<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994864</url>
  </required_header>
  <id_info>
    <org_study_id>PEPITA 001</org_study_id>
    <secondary_id>EudraCT number: 2009-011445-13</secondary_id>
    <nct_id>NCT00994864</nct_id>
  </id_info>
  <brief_title>Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer</brief_title>
  <acronym>PePiTA</acronym>
  <official_title>Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary working hypothesis is that preoperative chemo-sensitivity testing using
      fluorodeoxyglucose positron emission tomography (FDG-PET) performed before and after one
      course of FOLFOX (folinic acid, fluorouracil, oxaliplatin) can identify the patients that
      will least likely have a significant benefit from adjuvant FOLFOX for stage III colon cancer.
      The benefit will be analyzed by correlating the preoperative FDG-PET uptake changes to the
      disease free and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with histological confirmed colon adenocarcinoma compatible with clinical stage II
      or III are eligible for study screening. Receipt of a signed informed consent and study
      inclusion should be done within 15 days after histological diagnosis. A usual workup for
      preoperative staging of colon cancer must be done not more than 1 month before study
      inclusion and include CEA assessment, positive histological sample for colon adenocarcinoma
      and chest and abdominal CT scan. After receipt of the written consent, the patient undergoes
      baseline PET/CT scan and donates blood samples for CTC and SNP analyses. Delay between
      baseline examinations and histological diagnosis must not exceed 21 days. The baseline
      examinations should be done within 1 week before beginning of the first course of FOLFOX
      chemotherapy. Thirteen to 15 days after chemotherapy, the PET/CT and blood sampling for CTC
      analysis are repeated. Standard surgery follows after 15 days but no more than 30 days from
      Day 1 of preoperative chemotherapy. Two frozen tissue cores are obtained during surgery and
      sent immediately in dry ice shipping to the central Tumour Bank (Jules Bordet Institute) or
      stored locally at -80°C to be sent in batches to the central tumour bank. Thereafter, the
      patient receives standard care, according to tumour pathological stage. In fully eligible
      patients, FOLFOX chemotherapy should be started not more than 45 days after surgery. In stage
      III patients otherwise ineligible, recommendation is to start FOLFOX chemotherapy within 45
      days after surgery although such patients will not be included in the primary analysis.
      Treatment in case of stage II or stage IV colon cancer is left at investigator's discretion.
      Eleven courses of adjuvant FOLFOX are foreseen, in order to match the usual recommendation
      coming from the Mosaic Trial.

      Follow-up procedures after completion of adjuvant treatment will follow standard European
      clinical recommendations for stage II and III patients. Clinical follow-up data will be
      obtained for all patients, including those with stage II disease, with a minimum follow-up
      time of three years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.</measure>
    <time_frame>Within 3 years after completion of adjuvant chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine the predictive value of PET-assessed tumour FDG uptake changes after one course of preoperative chemotherapy on OS</measure>
    <time_frame>Within 3 years after completion of adjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the best cut-off value for relative delta SUV in assessment of preoperative chemotherapy response by FDG-PET/CT imaging.</measure>
    <time_frame>Within 3 years after completion of adjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the cost-effectiveness of preoperative chemo-sensitivity testing</measure>
    <time_frame>Within 3 years after completion of adjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the predictive value of circulating tumour cells on disease-free survival</measure>
    <time_frame>Within 3 years after completion of adjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the predictive value of SNPs on toxicity- and drug target-related genes on DFS</measure>
    <time_frame>Within 3 years after completion of adjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create a frozen tumour bank for future studies</measure>
    <time_frame>Within 2 years from the beginning of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant FOLFOX (1 pre-operative cycle)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.</description>
    <arm_group_label>adjuvant FOLFOX (1 pre-operative cycle)</arm_group_label>
    <other_name>FOLFOX-4 or equivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Clinical/radiological evaluation compatible with stage III colon adenocarcinoma

          -  No prior chemotherapy

          -  No prior abdominal or pelvic irradiation

          -  WHO performance status 0 or 1

          -  Effective contraception during the study and the following six months

          -  Signed informed consent obtained prior to any study-specific screening procedures

          -  Tumour considered as curatively resectable (R0) based on standard preoperative
             evaluations

          -  White blood cell count ≥ 3×109/L with neutrophils ≥ 1.5×109/L, platelet count ≥
             100×109/L, haemoglobin ≥ 9 g/dL (5.6 mmol/L)

          -  Direct bilirubin ≤ 1.5×ULN; ASAT and ALAT ≤ 2.5×ULN; Alkaline phosphatase ≤ 2.5×ULN;
             Serum creatinine ≤ 1.5×ULN

          -  Delay between assessment of screening criteria and first PET/CT &lt; 21 days

          -  Blood glucose &lt; 150 mg/dl at the time of FDG administration. Insulin or oral
             anti-diabetic medication is not allowed on the days of PET/CT imaging.

          -  Compliance to the first chemotherapy course to be administered before surgery

          -  Delay between the first PET/CT imaging and the start of neoadjuvant FOLOFX &lt; 7 days

          -  Second PET/CT imaging performed on D14 (range: D13-D15, with D1 as the first day of
             chemo administration)

          -  Delay between the second PET/CT and surgery &lt; 7 days

          -  Stage III (ypTNM) as assessed after surgery

          -  CEA &lt; 1.5 x ULN 1 month after surgery -

        Exclusion Criteria:

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to screening. Incompletely healed wounds or anticipation of the need for major
             surgical procedure during the course of the study

          -  Any suspicion of metastatic disease

          -  Rectal cancer located within 15 cm from the anal verge by endoscopy or under the
             peritoneal reflection at surgery

          -  Inflammatory bowel disease

          -  Pregnancy (absence to be confirmed by ß-hCG blood test) or breast-feeding

          -  History or current central nervous system disease or peripheral neuropathy

          -  Hypersensitivity to any of the components of study treatments

          -  Previous malignancy in the last five years except basal-cell carcinoma of the skin or
             in situ cervical carcinoma

          -  Clinically relevant coronary artery disease or history of myocardial infarction in the
             last 6 weeks or high risk of uncontrolled arrhythmia

          -  Medical, geographical, sociological, psychological or legal conditions that would not
             permit the patient to complete the study or sign informed consent

          -  Any significant disease which, in the investigator's opinion, would exclude the
             patient from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Hendlisz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Hendlisz, MD</last_name>
    <phone>2 5413541</phone>
    <phone_ext>0032</phone_ext>
    <email>alain.hendlisz@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Denis</last_name>
    <phone>2 5413196</phone>
    <phone_ext>0032</phone_ext>
    <email>anne.denis@bordet.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique St-Luc Bouge</name>
      <address>
        <city>Bouge</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marylene Clausse, MD</last_name>
      <email>marylene.clausse@ct-luc-bouge.be</email>
    </contact>
    <investigator>
      <last_name>Marylene Clausse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc Van Laethem, MD</last_name>
      <email>jl.vanlaethem@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc Van Laethem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Hendlisz, MD</last_name>
      <email>alain.hendlisz@bordet.be</email>
    </contact>
    <contact_backup>
      <last_name>Anne Denis</last_name>
      <email>anne.denis@bordet.be</email>
    </contact_backup>
    <investigator>
      <last_name>Alain Hendlisz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Efira, MD</last_name>
      <email>andre.efira@chu-brugmann.be</email>
    </contact>
    <investigator>
      <last_name>André Efira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRIS Etterbeek-Ixelles</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Kains, MD</last_name>
      <email>jpkains@his.irisnet.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Kains, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clin Université St-Luc Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Van Den Eynde, MD</last_name>
      <email>marc.vandeneynde@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Marc Van Den Eynde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIS IZZ Bracops</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Brenez</last_name>
      <email>dbrenez@his-izz.be</email>
    </contact>
    <investigator>
      <last_name>Daniel Brenez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JC Canon</last_name>
      <email>canon.jl@ghdc.be</email>
    </contact>
    <investigator>
      <last_name>JC Canon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Peeters, MD</last_name>
      <email>marc.peeters@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Marc Peeters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Laurent, MD</last_name>
      <email>stephanie.laurent@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Laurent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Vergauwe, MD</last_name>
      <email>philippe.vergauwe@azgroeninge.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Vergauwe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Delhougne, MD</last_name>
      <email>bernard.delhougne@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Bernard Delhougne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU De Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Polus, MD</last_name>
      <email>marc.polus@skynet.be</email>
    </contact>
    <investigator>
      <last_name>Marc Polus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique St-Joseph</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauthier Demolin</last_name>
      <email>gauthier.demolin@chc.be</email>
    </contact>
    <investigator>
      <last_name>Gauthier Demolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA - Jan Palfijin</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Vermeij, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joanna Vermeij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Holbrechts, Dr</last_name>
      <phone>32 65 4148 80</phone>
      <email>stephane.holbrechts@hap.be</email>
    </contact>
    <investigator>
      <last_name>Stephane Holbrechts, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Namur</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry De Grez, MD</last_name>
      <email>thierry.degrez@chrnamur.be</email>
    </contact>
    <investigator>
      <last_name>Thierry De Grez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Deboever, MD</last_name>
      <email>gdeboever@azdamiaan.be</email>
    </contact>
    <investigator>
      <last_name>Guido Deboever, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>clinique St Pierre Ottignies</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JC Coche</last_name>
      <email>jc.coche@clinique-saint-pierre.be</email>
    </contact>
    <investigator>
      <last_name>JC Coche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Janssens</last_name>
      <email>jos.janssens@azturnhout.be</email>
    </contact>
    <investigator>
      <last_name>Jos Janssens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Universites UCL Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel D'Hondt, MD</last_name>
      <email>lionel.dhondt@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Lionel D'Hondt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

